Please join us for an in-person event
Data Disclosure Considerations and Best Practices for Publicly Traded Drug Development Companies
Navigating Securities and Exchange Commission (SEC) disclosure requirements and considerations can present some of the most complex, challenging and nuanced questions for in-house lawyers and compliance professionals at clinical-stage and early commercial stage drug development companies. The implementation of rigorous disclosure controls and infrastructure to manage these questions in a compliant and business-oriented manner is essential.
Our panel of SEC compliance, FDA regulatory and securities litigation partners will address the following topics:
- Compliance and disclosure best practices for drug development companies (including the use of trading blackout periods, disclosure review committees, and managing sensitive disclosure windows around other SEC filings and capital markets activity)
- Interacting with the FDA, and guidance on disclosure from the agency
- Recent Regulation FD enforcement actions involving the life sciences/drug development industry
- Assessing materiality for disclosure purposes throughout a company’s life cycle and evolution
- Mitigating risk of liability under the federal securities laws
Date: Wednesday, March 5, 2025
Time: 4 - 6:30 p.m.
Location: The Lexington | 100 N First St, 2nd Floor Cambridge, MA 02141
